# Modeling treatment of diabetic wounds with oxygen therapy and senolytic drug

**Authors:** Nourridine Siewe, Avner Friedman

PMC · DOI: 10.1038/s41598-025-02852-9 · Scientific Reports · 2025-05-23

## TL;DR

This paper presents a mathematical model to predict how diabetic wounds respond to oxygen therapy and senolytic drugs, based on aging-related biological parameters.

## Contribution

The novelty is a model that combines hyperbaric oxygen therapy and senolytic drugs to improve wound healing in aging diabetic patients.

## Key findings

- HBOT alone heals wounds only in patients with specific aging parameter pairs.
- Combining quercetin with HBOT increases the subset of patients who can benefit from treatment.
- The model identifies distinct subsets of aging parameters that respond to each treatment.

## Abstract

Diabetic wounds are common in patients with type 2 diabetes; they are ischemic and inflammatory, and difficult to heal without intervention. Hyperbaric oxygen therapy (HBOT) is a standard treatment, but its effectiveness is limited to a subset of the aging population. Senescent fibroblasts, a hallmark of aging, impair wound healing, and senolytic drugs, like quercetin (Q), which target senescent cells, may improve healing. In this study, we developed a mathematical model that defines biological aging through two parameters, \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\eta$$\end{document} and \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A_0$$\end{document}, that decline with age. These parameters reflect the biological age of an individual, where \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\eta$$\end{document} represents fibroblast proliferation and \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A_0$$\end{document} represents the production of the angiogenetic protein VEGF. Our model predicts that treatment with only HBOT achieves wound closure, within normal expectable time, for patients with a limited subset pairs of \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$(\eta ,A_0)$$\end{document}, and this subset is increased to a larger subset by combining Q with HBOT. The two subsets of \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$(\eta ,A_0)$$\end{document} are determined explicitly by simulations of the model. To make these results applicable in clinical setting, one will have to relate the aging parameters \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\eta$$\end{document} and \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A_0$$\end{document} to tangible marks of biological-aging factors.

## Linked entities

- **Proteins:** VEGFA (vascular endothelial growth factor A)
- **Chemicals:** quercetin (PubChem CID 5280343)
- **Diseases:** type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** inflammatory (MESH:D007249), Diabetic wounds (MESH:D003920), ischemic (MESH:D002545), type 2 diabetes (MESH:D003924)
- **Chemicals:** oxygen (MESH:D010100), quercetin (MESH:D011794), Q (MESH:D005973)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12102321/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12102321/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12102321/full.md

---
Source: https://tomesphere.com/paper/PMC12102321